Although MF was able to attenuate HSC activation and liver fibrosis by inhibiting TGF-β1/SMADs and NOX4/ROS signaling pathways (Cheng et al., 2019), there was no alteration of PTP1B activity observed after MF administration. The gene discussed is TGFB1; the disease is Hepatic fibrosis.